Catalyst Pharmaceuticals Inc’s recently made public that its Officer Elsbernd Brian acquired Company’s shares for reported $0.61 million on Sep 08 ’25. In the deal valued at $20.30 per share,30,000 shares were bought.
Then, Elsbernd Brian sold 30,000 shares, generating $585,600 in total proceeds. Upon selling the shares at $19.52, the Chief Compliance/Legal Officer now owns 188,564 shares.
Before that, Elsbernd Brian sold 20,000 shares. Catalyst Pharmaceuticals Inc shares valued at $401,600 were divested by the Chief Compliance/Legal Officer at a price of $20.08 per share. As a result of the transaction, Elsbernd Brian now holds 188,564 shares, worth roughly $3.77 million.
Robert W. Baird initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to an Outperform in a research note published on February 04, 2025; the price target was $28. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid November with a ‘”an Overweight”‘ rating. Citigroup began covering CPRX with “Buy” recommendation on March 14, 2024. BofA Securities started covering the stock on March 07, 2024. It rated CPRX as “a Buy”.
Price Performance Review of CPRX
On Tuesday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock fall -0.40% to $20.0. Over the last five days, the stock has lost -2.63%. Catalyst Pharmaceuticals Inc shares have risen nearly 0.91% since the year began. Nevertheless, the stocks have fallen -4.17% over the past one year. While a 52-week high of $26.58 was reached on 06/09/25, a 52-week low of $19.00 was recorded on 08/07/25.
Levels Of Support And Resistance For CPRX Stock
The 24-hour chart illustrates a support level at 19.82, which if violated will result in even more drops to 19.63. On the upside, there is a resistance level at 20.33. A further resistance level may holdings at 20.66.
How much short interest is there in Catalyst Pharmaceuticals Inc?
A steep rise in short interest was recorded in Catalyst Pharmaceuticals Inc stocks on 2025-08-15, growing by 23703.0 shares to a total of 8.94 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 8.92 million shares. There was a rise of 0.27%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 21, 2023 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
